TP53 and neoplasm: On the other hand, in the early stage of urothelial cancer, where CDK9 expression is the highest, CDK9 inhibition can inhibit transcription of anti-apoptotic proteins, impair tumor growth, reactivate wild-type p53 and increase its concentration, thereby preventing disease progression [12,47,54].